Fulgent Genetics (NASDAQ:FLGT) Updates FY25 Earnings Guidance

Fulgent Genetics (NASDAQ:FLGT) updated its FY25 earnings guidance on Friday. The company provided earnings per share guidance of $(0.65) for the period, compared to the consensus earnings per share estimate of ($0.15). The company issued revenue guidance of $310.0 million, compared to the consensus revenue estimate of $324.65 million. Fulgent Genetics also updated its FY 2025 guidance to -0.650–0.650 EPS.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on FLGT. Piper Sandler dropped their price objective on shares of Fulgent Genetics from $26.00 to $22.00 and set a “neutral” rating on the stock in a report on Monday, November 11th. StockNews.com lowered shares of Fulgent Genetics from a “hold” rating to a “sell” rating in a report on Wednesday, November 27th.

Fulgent Genetics Price Performance

Shares of FLGT opened at $15.45 on Friday. The firm has a market capitalization of $472.57 million, a PE ratio of -2.80 and a beta of 1.39. Fulgent Genetics has a 1-year low of $15.21 and a 1-year high of $25.11. The company’s fifty day moving average price is $17.32 and its 200-day moving average price is $19.49.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.